Resource Center
Resource Center
By 2035, insulin treatment in LMICs will double to 76 million—but 30 million people will still lack access, our new market memo reveals.
Read more
CHAI has released new analysis examining contraceptive access across multiple African countries in the months following the end of USAID's reproductive health programs in early 2025.
Read more
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI.
Read more
ABUJA, NIGERIA, October 21, 2025: Today, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat cancer. The goal of the initiative is to develop an approach that explores sustainable and effective administration of innovative immuno-oncology therapies in...
Read more
Tuberculosis (TB) is the world’s deadliest infectious disease, killing over a million people annually. While the century-old BCG vaccine protects young children, it leaves adolescents and adults vulnerable—and they’re the ones who are most likely to spread TB. New vaccines targeting this gap could arrive by 2030, but countries, manufacturers, and funders need to prepare...
Read more
In 12 months, Nigeria's presidential initiative screened 1.5 million people and distributed over a million free reading glasses—with CHAI and partners contributing 800,000 pairs across 10 states.
Read more
This year's report checks in with our 2024-2028 strategy and our work to tackle persistent global health challenges even as the global health landscape has shifted.
Read more
CHAI has released the inaugural edition of its Triple Elimination Series, a set of market briefs examining market-shaping strategies to prevent vertical transmission of HIV, syphilis, and hepatitis B (commonly known as triple elimination). This first brief focuses on the introduction and scale-up of HIV/syphilis dual rapid diagnostic tests (RDTs), drawing on CHAI’s experience working...
Read more
The revolutionary HIV prevention tool, injectable lenacapavir, will be available at a cost of US$40 a year in 120 low- and middle-income countries starting in 2027, under a new partnership announced today between Dr. Reddy’s Laboratories and Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI.
Read more
As world leaders gather in New York this week for the UN High-Level Meeting on Non-Communicable Diseases and Mental Health, they’re confronting a stark reality: non-communicable diseases (NCDs) kill more people than any other cause globally yet receive only a fraction of health funding. But what if the solution isn’t just more money—what if it’s...
Read more